Lapatinib in the treatment of HER-2 overexpressing breast cancer.

Vrdoljak, E; Boban, M; Ban, M

Vrdoljak, E; Boban, M; Ban, M.

Affiliation

Vrdoljak E; Center of Oncology, Clinical Hospital Split, Split, Croatia. eduard.vrdoljak@st.t-com.hr

J BUON ; 16(3): 393-9, 2011.

Article in En | MEDLINE | ID: mdl-22006739

Subject(s)

Antineoplastic Agents/therapeutic use; Breast Neoplasms/drug therapy; Quinazolines/therapeutic use; Receptor, ErbB-2/analysis; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/chemistry; Breast Neoplasms/pathology; Clinical Trials as Topic; Female; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines/adverse effects

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Breast Neoplasms / Receptor, ErbB-2 / Antineoplastic Agents Limits: Female / Humans Language: En Journal: J BUON Journal subject: NEOPLASIAS Year: 2011 Document type: Article Affiliation country: Croatia Country of publication: Cyprus

Search on Google

Add to My VHL

XML

PubMed Links